Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2137
Abstract: Patritumab deruxtecan is an antibody–drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide‐based cleavable linker. As part… read more here.
Keywords: clearance; patritumab deruxtecan; dxd; population pharmacokinetics ... See more keywords
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer
Sign Up to like & getrecommendations! Published in 2024 at "Gastric Cancer"
DOI: 10.1007/s10120-024-01478-6
Abstract: HER2-targeted therapies have improved the outcomes of HER2-positive gastric cancer (GC), yet resistance remains a challenge. We sought to explore the effects of reversible and irreversible HER2 tyrosine kinase inhibitors (TKIs) alone or in combination… read more here.
Keywords: dxd; her2 tkis; gastric cancer; irreversible her2 ... See more keywords
Trastuzumab-Deruxtecan beim HER2-positiven metastasierten Mammakarzinom
Sign Up to like & getrecommendations! Published in 2024 at "Geburtshilfe und Frauenheilkunde"
DOI: 10.1055/a-2326-3843
Abstract: Trastuzumab-Deruxtecan (T-DXd) ist ein Antikörper-Wirkstoffkonjugat (Antibody Drug-Conjugate; ADC), das aus einem humanisierten monoklonalen HER2-IgG1-Antikörper mit der gleichen Aminosäuresequenz wie Trastzumab, dem Topoisomerase-I-Inhibitor Deruxtecan (DXd) sowie einem enzymatisch spaltbaren Linker auf TetrapeptidBasis besteht. Die Wirksamkeit von… read more here.
Keywords: her2 positiven; mit; dxd; der ... See more keywords
Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-c041
Abstract: Background: Anti-HER2 therapies are beneficial for patients with HER2+ gastric or breast cancer (BC). [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody (Ab) conjugated by a peptide-based… read more here.
Keywords: dxd; study; breast cancer; fam trastuzumab ... See more keywords
Abstract A095: Tolerability and ocular adverse events of Datopotamab Deruxtecan in advanced cancers: A meta-analysis of phase III trials
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a095
Abstract: Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate composed of a TROP2-targeting monoclonal antibody linked to a topoisomerase I inhibitor. It received FDA approval in January 2025 for unresectable or metastatic HR-positive, HER2-negative breast cancer… read more here.
Keywords: phase iii; adverse events; dxd; meta analysis ... See more keywords
Abstract B009: Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-b009
Abstract: Azenosertib (ZN-c3) is a selective, orally bioavailable WEE1 kinase inhibitor. Trastuzumab deruxtecan (T-DXd; DS-8201a) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate that delivers a topoisomerase 1 inhibitor payload. In preclinical studies,… read more here.
Keywords: cancer; dxd; combination; solid tumors ... See more keywords
Abstract 2273: Soluble TNFα blockade improves effectiveness of trastuzumab deruxtecan and boosts antitumor potential of macrophages in a HER2+ tumor model
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2273
Abstract: Clinical trials showed that trastuzumab deruxtecan (T-DXd) provides durable responses for patients with HER2+ and HER2 low metastatic breast cancer (BC), determined by immunohistochemistry. Approximately 50% of patients with HER2+ metastatic BC were still alive… read more here.
Keywords: trastuzumab deruxtecan; dxd dxd; dxd; blockade ... See more keywords
Abstract 2932: Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1/PD-L1 inhibitors in TROP2-expressing tumors in mice
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2932
Abstract: Background: Trophoblast cell surface antigen 2 (TROP2) is highly expressed in various epithelial tumors, including non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC), and correlates with poor prognosis. Datopotamab deruxtecan (Dato-DXd) is… read more here.
Keywords: dato dxd; antitumor activity; htrop2 mc38; dxd ... See more keywords
Abstract 3995: Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, effectively inhibits growth of patient-derived xenograft model with CIC-rearranged sarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3995
Abstract: Background: Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS) are extremely rare and highly aggressive sarcomas. There is no standard therapy for the patients with advanced CDS, and therapeutic development is needed. We evaluated preclinical efficacy of… read more here.
Keywords: cic; pdx; dxd; patient derived ... See more keywords
Abstract CT058: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct058
Abstract: Background: Pts with metastatic epithelial tumors who progress after initial therapy have a poor prognosis; new therapeutic agents could potentially improve outcomes. Trophoblast cell surface protein 2 (TROP2) is a transmembrane glycoprotein that is over-expressed… read more here.
Keywords: dato dxd; dxd monotherapy; combination; dxd ... See more keywords
Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1088
Abstract: Introduction: HER3-DXd is an ADC consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload (DXd, an exatecan derivative) that has demonstrated clinically meaningful efficacy with durable responses in… read more here.
Keywords: rms models; her3 dxd; pdx models; dxd ... See more keywords